October 2024
Breakthrough in Cryptosporidiosis Treatment: New Drugs Show Promise in Animal Models
Cryptosporidiosis, new treatments, animal models, drug development, parasitic diseases
Fierce Pharma AsiaAstellas’ first-in-class FDA nod; Otsuka’s IgAN win; Samsung Bio’s $1.2B contract
United States Food and Drug Administration, IGA Glomerulonephritis, Sibeprenlimab, Contract agreement, Samsung, first
Astellas Secures FDA Approval for Vyloy, a First-in-Class Claudin-Targeted Therapy for Gastric Cancers
Astellas, Vyloy, FDA Approval, Claudin 18.2, Gastric Cancer, Gastroesophageal Junction Cancer, HER2-negative, Zolbetuximab
Merck’s KEYTRUDA Receives 30th European Approval for Gynecologic Cancers
KEYTRUDA, pembrolizumab, European Commission, gynecologic cancers, endometrial cancer, cervical cancer, cancer treatment, immunotherapy.
Tyra Biosciences Unveils Early Data for FGFR3 Inhibitor, TYRA-300, in Challenge to J&J’s Balversa
Tyra Biosciences, TYRA-300, Balversa, J&J, bladder cancer, urothelial carcinoma, FGFR3 inhibitor, safety concerns, efficacy data
Intellia’s CRISPR Therapy NTLA-2002 Shows 81% Reduction in Hereditary Angioedema Attacks in Phase 2 Study
CRISPR therapy, Intellia Therapeutics, NTLA-2002, Hereditary Angioedema (HAE), Gene editing, Phase 2 study, Swelling attacks, Functional cure
Bayer and Dewpoint Therapeutics Collaborate on Dilated Cardiomyopathy Program with $424 Million Deal
Bayer, Dewpoint Therapeutics, Dilated Cardiomyopathy, DCM, Pharmaceutical Deal
Intellia’s CRISPR Gene Editing Therapy Shows Promising Results in Reducing HAE Attacks
Intellia Therapeutics, CRISPR Gene Editing, Hereditary Angioedema (HAE), NTLA-2002, Clinical Trials, Gene Therapy, Rare Diseases
CDC Recommends Pneumococcal Vaccination for Adults 50 Years and Older
Pneumococcal vaccination, CDC recommendations, adults 50 and older, pneumococcal disease prevention, winter respiratory season.
Roche and Dyno Therapeutics Launch $1B+ Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Neurological Diseases
Roche, Dyno Therapeutics, AAV gene therapy vectors, Neurological diseases, AI-driven gene delivery, LEAP technology, Gene therapy collaboration